Should heart transplantation be considered as a treatment option for patients aged 70 years and older?  by Morgan, Jeffrey A et al.
Brief Communicationsof aortic arch rupture, we could not remove the covered portion of
the endoprosthesis by pulling it. We had to cut and remove each
branch separately, which extended the duration of circulatory
arrest significantly. The proximal suture of the arch reconstruction
was difficult to perform because of fibrosis of the tissues.
In our case femoral vein cannulation was impossible; the can-
nula stopped in the iliac vein with the patient in the left thoracot-
omy position as well as the dorsal decubitus position. A good
venous return is needed for circulatory arrest, so we cannulated the
pulmonary artery trunk This kind of cannulation entails consider-
able risk because of the fragility of the tissue, and the pulmonary
artery may be torn when cannulated. Moreover, occluding the
cannula to avoid leakage of blood is difficult.
We found a large communication between the two channels
facing the proximal uncovered part of the stent. We do not know
whether this communication existed before or was caused by the
insertion of the stent, but it was the cause of failed endovascular
treatment in our case. We did not use a balloon to expand the stent
when deploying the endoprosthesis to avoid any risk of creating a
communication between the two channels.
These findings suggest the difficulties associated with the en-Jeffrey A. Morgan, MD, Ranjit John, MD, Donna M. Mancini, M
The Journal of Thoracicreentry points between the two lumina may be found on the
descending thoracic aorta, making endovascular treatment hazard-
ous. If secondary surgery is required, the repair is more difficult
than it is in primary surgery because aortic crossclamping is
impossible. Therefore the explantation of the endoprosthesis and
the reconstruction of the aortic arch must be done under circulatory
arrest. The explantation of the stent graft is also technically diffi-
cult, because it is deeply embedded in the aortic wall.
We thank Nancy Richardson-Peuteuil for her editorial assis-
tance.
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Should heart transplantation be considered as a treatment option for
patients aged 70 years and older?D, and Niloo M. Edwards, MD, New York, NYSeveral studies have demonstrated favorable results afterorthotopic cardiac transplantation in recipients of ad-vanced age.1-4 These studies have demonstrated similarsurvival in elderly patients as compared to that of
younger patients undergoing heart transplantation. This has re-
sulted in a relaxation of the upper age limit for cardiac transplan-
tation in many centers. However, some transplant centers continue
to view advanced recipient age as a contraindication to transplan-
tation because of concerns regarding decreased survival in this
cohort.5-7 This study was conducted to analyze and compare our
experiences with older (70 years and older) versus younger
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and long-term survivals.
Patients and Methods
Between January 1992 and February 2003, a total of 939 ortho-
topic cardiac transplants were performed at the New York Pres-
byterian Hospital–Columbia Medical Center, New York. Of these,
10 (1.1%) were performed in patients 70 years old or older (range
70.2-74.8 years). These patients were compared with patients
younger than 70 years (range 18.3-69.8 years) at the time of
transplantation. Pediatric patients (younger than 18 years; n 
115) were excluded. Outcome measures included perioperative
and long-term posttransplantation survivals.
Statistical analysis. Data were represented as frequency dis-
tributions and percentages. Values of continuous variables were
expressed as mean  SD. Continuous variables were compared
with paired t tests, whereas categorical variables were compared
by means of 2 tests. Kaplan-Meier analysis was used to calculate
survival along with a log-rank P value when comparing groups.
Actuarial survivals at 1, 3, 5, and 10 years after transplantation
were calculated by constructing life tables. Significant predictors
of mortality were identified with multivariate Cox proportional
hazard models. All data were analyzed with the SPSS 11.5 soft-
ware package (SPSS Inc, Chicago, Ill).
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Recipient data. Table 1 outlines the baseline clinical demo-
graphic data of patients in both groups. Mean ages were 72.2 1.6
years (70.2-74.8 years) in the older group and 51.6  12.6 years
(18.3-69.8 years) in the younger group (P  .001). Sex and
ethnicity distributions were similar in both groups (P  .339, P 
.296, P  .229, P  .879). Left ventricular assist devices were
present in a greater percentage of patients younger than 70 years
(21.5% vs 0.0%), although the difference was not statistically
significant (P .099). There were no retransplantations in patients
70 years or older, versus 45 (5.5%) in patients younger than 70
years.
Donor data. There was no statistically significant difference in
donor ischemic time between the groups, although donor ischemic
time was higher in the older group (195.0  50.9 minutes for 70
years and older vs 175.7 61.4 minutes for younger than 70 years,
P  .157). There was a trend toward significance for increased
donor age in the older group (41.6  16.3 years for 70 years and
older vs 32.2  13.1 years for younger than 70 years, P  .061).
Survival. Overall survivals are depicted in Figure 1. There was
no statistically significant difference in long-term survival between
the groups (P  .790). Actuarial survivals at 1, 3, 5, and 10 years
were 89.5%, 89.5%, 89.5%, and 44.7%, respectively, for the older
group, and 83.6%, 77.9%, 72.0%, and 51.8%, respectively, for the
younger group.
Cox proportional hazard models. Advanced recipient age was
not an independent predictor of adverse outcome in multivariate
analysis (odds ratio 0.464, 95% confidence interval 0.246-0.688, P
 .851, standard error 0.278).
Discussion
With increases in life expectancy and thus in the elderly popula-
TABLE 1. Baseline clinical characteristics of patients
Variable >70 y <70 y
P
value*
Recipient characteristics
Age (y, mean  SD) 72.2 1.6 51.6 12.6 .001
Sex (No.)
Male 9 (90.0%) 629 (77.3%) .339
Female 1 (10.0%) 185 (22.7%)
Race (No.)
White 9 (90.0%) 617 (75.8%) .296
Black 0 (0.0%) 103 (12.7%) .229
Other 1 (10.0%) 94 (11.5%) .879
Height (cm, mean  SD) 179.8 6.0 172.1 11.1 .068
Weight (kg, mean  SD) 75.4 18.7 74.0 15.9 .812
Left ventricular assist
device (No.)
0 (0.0%) 175 (21.5%) .099
Male-female mismatch
(No.)
5 (50.0%) 464 (57.0%) .657
Retransplantation (No.) 0 (0.0%) 45 (5.5%) .444
Donor characteristics
Donor ischemic time
(min, mean SD)
195.0 50.9 175.7 61.4 .157
Age (y, mean  SD) 41.6 16.3 32.2 13.1 .061
*P value from independent samples t tests.tion, more elderly patients are being seen by cardiologists and
1818 The Journal of Thoracic and Cardiovascular Surgery ● Juncardiac surgeons for end-stage heart failure.8 There is an increased
need for cardiac surgical procedures in the elderly population.8
Although transplantation is an effective treatment for end-stage
heart failure, many transplant centers are reluctant to perform
transplantation in elderly patients, even though there are data that
indicate that this subgroup of patients can undergo transplantation
with a survival similar to that of younger recipients.9-11
In our series of patients 70 years old or older at the time of
transplantation, there was no significant difference in short or
long-term survival with respect to patients younger than 70 years.
Recipient age was not a risk factor for mortality and should not
serve as a contraindication for transplantation. Limitations of this
study include those related to a retrospectively performed analysis.
Identification of clinical variables was obtained by chart review,
which has inherent limitations, such as access and incompleteness
of the data. Notwithstanding these limitations, our results argue
that elderly patients should not be denied transplantation solely on
the basis of advanced age. These patients deserve a careful medical
evaluation to determine whether they are appropriate transplant
candidates. When the procedure is performed in carefully selected
elderly patients, it is associated with an outcome similar to that in
younger patients.
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J Thorac Cardiovasc Surg. 1999;117:939-51.Superior vena cava stenosis: A delayed BioGlue complication
George C. Economopoulos, MD,a George K. Dimitrakakis, MD,a E. Brountzos, MD,b and D. A. Kelekis, MD,bWe report a case of superior vena cava (SVC) ste-nosis with upper body venous hypertension afterapplication of biologic glue in the vicinity of theSVC after a double valve replacement and an
annuloplasty procedure. The SVC stenosis was managed success-
fully with balloon dilatation and stent placement.
Clinical Summary
A 63-year-old man was scheduled for double (aortic and mitral)
valve replacement and tricuspid valve annuloplasty. Bicaval can-
nulation was performed through the right atrial appendage for the
SVC and the atriocaval junction for the inferior vena cava; stan-
dard ascending aortic cannulation was also performed. Antegrade
and retrograde cold blood cardioplegia with moderate core hypo-
thermia (30°C) constituted the cardioprotective strategy. The ex-
posure of mitral and tricuspid valves was obtained through a
superior transseptal approach; exposure of the aortic valve was
obtained through a transverse aortotomy. After the mitral and the
aortic valve replacements, a DeVega tricuspid valve annuloplasty,
and closure of the atriotomy incision, there was persistent bleeding
from the dome of the left atrium. Despite adequate suturing, local
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doi:10.1016/j.jtcvs.2003.12.041sponge packing, reversal of all anticoagulants, and plasma and
platelet transfusions, the oozing persisted. A fair amount of Bio-
Glue (Cryolife, Inc, Kennesaw, Ga) was placed on the area, with
a successful result. The patient had an uneventful recovery, and he
was discharged on the ninth postoperative day.
The patient returned 8 months later, reporting headaches, diz-
ziness especially on bending, and significant swelling of the face
and neck. Echocardiography revealed a competent tricuspid valve
repair and two well-functioning artificial valves, with satisfactory
myocardial performance. A retroaortic and paracaval echodense
mass was noted to be compressing the SVC at its junction with the
right atrium (Figure 1). An upper-body venogram revealed a
severe stenosis (90%) of the SVC (Figure 2, A). Dilatation of the
SVC with 7-mm and 12-mm balloons, followed by placement of a
12  64-mm Wallstent (Boston Scientific, Watertown, Mass),
successfully relieved the stenosis (Figure 2, B). The patient is
doing well without recurrent stenosis 16 months after the proce-
dure.
Discussion
After the adverse effects of cyanoacrylate-based glue on the aortic
tissues became apparent,1-3 a new bovine albumin–based glue
cross-linked with glutaraldehyde, BioGlue, was introduced into the
cardiac surgical market as the new, nontoxic glue for hemostasis.
The product is a preparation of bovine albumin cross-linked with
glutaraldehyde to form a strong adhesive bond. It is supplied in a
two-barrel applicator; the two compartments contain albumin and
glutaraldehyde, which are mixed at the time of application. After
mixture, the glue solidifies in about 30 seconds and achieves
maximum strength in about 2 to 3 minutes.4 The use of BioGlue in
aortic surgery was met with great initial enthusiasm, because not
only did it increase the strength of the friable aortic walls in aortic
dissection when it was applied between the dissected aortic layers,
it was proved effective as a sealing agent at the anastomotic suture
5-8line.
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